Home › Free Stock Grades › CGON
CG Oncology Inc. (CGON) Stock Grade
CGON · Healthcare
C
Market Cap
$6.1B
P/E Ratio
—
Revenue Growth (YoY)
+254.7%
Net Margin
-3985.0%
Return on Equity
—
Dividend Yield
None
About CG Oncology Inc.'s fundamentals
CG Oncology is a biotechnology company with a market capitalization of $6.1 billion that demonstrated exceptional revenue growth of 254.7% year-over-year, indicating rapidly expanding commercial activity. However, the company is currently unprofitable, reporting a net loss in its latest annual statement with a net margin of -3985.0%, reflecting substantial operating expenses that far exceed revenue. The company does not pay a dividend, which is typical for early-stage biotech firms prioritizing reinvestment in research and development.